GATEWAY Phase 2 Study: Short-Term Clinical Trial Opportunity for Adults with EPP
The GATEWAY Phase 2 Study is enrolling adults with Erythropoietic Protoporphyria (EPP) to test a potential new treatment.
Some Details:
The study takes place in Phoenix, Arizona
Travel, hotel, and meals are covered for you (and a caregiver/travel partner, if wanted)
US and international participants welcome
9 Days at the study site + travel days
Compensation provided for your time
You may qualify if you:
Are 18 or older with a confirmed EPP diagnosis (EPP only)
Experience symptoms within 40 minutes of sun exposure (can be on an approved drug, cannot be in another clinical trial)
Are a non-smoker or willing to stop 30 days prior to participating in study
Other inclusion/exclusion criteria will apply
To learn more: Contact Kristen Wheeden directly through the form below or at 301-461-9889.